Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 34454674

Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet
Publication date
2021 Aug 28
First author
Sun JM

This record carries publication-notice metadata. Review the notices below before relying on it.

Publication notices

absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet. 2021 Aug 28;398(10302):726-727. doi: 10.1016/S0140-6736(21)01607-X.
    note
    Source null
    related pmid
    34454657
    relationship
    Comment in
  2. citation
    Lancet. 2021 Nov 20;398(10314):1874. doi: 10.1016/S0140-6736(21)02487-9.
    note
    Source null
    related pmid
    34801105
    relationship
    Erratum in

Authors and identifiers

  1. name
    Sun JM
    type
    Author
  2. name
    Shen L
    type
    Author
  3. name
    Shah MA
    type
    Author
  4. name
    Enzinger P
    type
    Author
  5. name
    Adenis A
    type
    Author
  6. name
    Doi T
    type
    Author
  7. name
    Kojima T
    type
    Author
  8. name
    Metges JP
    type
    Author
  9. name
    Li Z
    type
    Author
  10. name
    Kim SB
    type
    Author
  11. name
    Cho BC
    type
    Author
  12. name
    Mansoor W
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Sun JM
    type
    Author
  2. name
    Shen L
    type
    Author
  3. name
    Shah MA
    type
    Author
  4. name
    Enzinger P
    type
    Author
  5. name
    Adenis A
    type
    Author
  6. name
    Doi T
    type
    Author
  7. name
    Kojima T
    type
    Author
  8. name
    Metges JP
    type
    Author
  9. name
    Li Z
    type
    Author
  10. name
    Kim SB
    type
    Author
  11. name
    Cho BC
    type
    Author
  12. name
    Mansoor W
    type
    Author
bibliography ids
  1. nci-bib-002f2b49d6817453f6f1738a
book metadata
content sha256
bc2ce397734bb6861c7fa1a687173c7670e96e4ad168d5cdc6724530345b4003
document type
citation
dois
  1. 10.1016/S0140-6736(21)01234-4
electronic publication date
display
Source null
precision
missing
year
Source null
evidence scope
bibliographic_metadata_only
id
pubmed:34454674
immutable id
pubmed:34454674@bc2ce397734bb6861c7fa1a687173c7670e96e4ad168d5cdc6724530345b4003
journal
abbreviation
Lancet
issn electronic
1474-547X
issn print
0140-6736
issue
10302
name
Lancet (London, England)
nlm unique id
2985213R
pages
759-771
volume
398
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet. 2021 Aug 28;398(10302):726-727. doi: 10.1016/S0140-6736(21)01607-X.
    note
    Source null
    related pmid
    34454657
    relationship
    Comment in
  2. citation
    Lancet. 2021 Nov 20;398(10314):1874. doi: 10.1016/S0140-6736(21)02487-9.
    note
    Source null
    related pmid
    34801105
    relationship
    Erratum in
outcomes validated
false
pmid
34454674
provenance
batch id
192b6392c165c6b06274
provider
NCBI PubMed ESummary
record sha256
642305b734df99a38c400211a2c676bf91c09e59975fccabc59d12a81cfa21d0
response sha256
7d81e9fb11ee99e6ad4116aecd61ba71cd6bf76f2a8f8f6d15c5c85e9c6c56b4
retrieved at
2026-09-09T23:48:02.713075+00:00
publication date
display
2021 Aug 28
precision
day
year
2021
publication types
  1. Clinical Trial, Phase III
  2. Journal Article
  3. Randomized Controlled Trial
  4. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/34454674/
title
Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study.

Preserved source evidence · Not medical advice